Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice...

Area of Science:

• Hematology
• Oncology
• Clinical Diagnostics

Background:

• Measurable/minimal residual disease (MRD) is a key prognostic factor for progression-free and overall survival in multiple myeloma (MM).
• MRD status can inform therapeutic decisions in MM management.

Purpose of the Study:

• To provide an overview of the current landscape of MRD testing in multiple myeloma within Canada.
• To highlight existing MRD testing approaches, identify barriers, and discuss available assays.
• To offer consensus recommendations on MRD testing timepoints and the significance of sustained MRD negativity.

Main Methods:

• A consensus-building process involving Canadian hematologists, clinical trial investigators, laboratory personnel, and MM patients.
• Consideration of the Canadian therapeutic landscape and upcoming regulatory approvals for MRD assays.

Main Results:

• The study outlines the current utilization and methodologies of MRD testing in Canadian MM care.
• Barriers to routine MRD testing and the suitability of various assays for clinical practice and trials are addressed.
• Recommendations are provided regarding optimal timing for MRD assessment and the clinical value of achieving durable MRD negativity.

Conclusions:

• Standardizing MRD testing in multiple myeloma is essential for improving prognostic accuracy and guiding treatment strategies in Canada.
• Addressing identified barriers and clarifying assay appropriateness will facilitate wider adoption of MRD testing.
• Achieving and maintaining MRD negativity represents a significant goal in optimizing patient outcomes in multiple myeloma.